Treatment Options in Alzheimer’s Disease: Maximizing Benefit, Managing Expectations

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Dementia and Geriatric Cognitive Disorders

• Publication date

  2008-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000122962PMID 18391487
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ginkgo biloba for cognitive impairment and dementia.

  2009cited by this paper
• Leisure activities and the risk of dementia in the elderly

  2009cited by this paper
• Neuroprotective and symptomatological action of memantine relevant for alzheimer’s disease — a unified glutamatergic hypothesis on the mechanism of action

  2009cited by this paper
• PREDICTORS OF PROGRESSION FROM MILD COGNITIVE IMPAIRMENT TO ALZHEIMER DISEASE

  2008influential reference
• Predictors of progression from mild cognitive impairment to Alzheimer disease

  2007cited by this paper
• Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.

  2007cited by this paper
• Incidence of dementia in mild cognitive impairment in the cardiovascular health study cognition study.

  2007influential reference
• Accounting for the relationship between low education and dementia: a twin study.

  2007cited by this paper
• WITHDRAWN: Reality orientation for dementia.

  2007cited by this paper
• Evidence-based psychological treatments for disruptive behaviors in individuals with dementia.

  2007cited by this paper
• Conversion from subtypes of mild cognitive impairment to Alzheimer dementia

  2007influential reference
• Ginkgo biloba Special Extract in Dementia with Neuropsychiatric Features

  2007cited by this paper
• Ginkgo biloba for cognitive impairment and dementia.

  2007cited by this paper
• CONVERSION FROM SUBTYPES OF MILD COGNITIVE IMPAIRMENT TO ALZHEIMER DEMENTIA

  2007cited by this paper
• Galantamine for Alzheimer’s Disease and Mild Cognitive Impairment

  2007cited by this paper
• Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease

  2007cited by this paper
• Leisure activities and the risk of dementia in the elderly

  2007cited by this paper
• Procedures for identifying evidence-based psychological treatments for older adults.

  2007cited by this paper
• Body mass index in midlife and risk of Alzheimer disease and vascular dementia.

  2007cited by this paper
• Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.

  2007cited by this paper
• Meta‐analysis of six‐month memantine trials in Alzheimer's disease

  2007cited by this paper
• Donepezil: an update

  2007cited by this paper
• Increased tau protein differentiates mild cognitive impairment from geriatric depression and predicts conversion to dementia.

  2007influential reference
• Evidence-based psychological treatments for distress in family caregivers of older adults.

  2007cited by this paper
• Hormone therapy, timing of initiation, and cognition in women aged older than 60 years: the REMEMBER pilot study

  2006cited by this paper
• 3-Year Study of Donepezil Therapy in Alzheimer’s Disease: Effects of Early and Continuous Therapy

  2006cited by this paper
• Mild cognitive impairment

  2006cited by this paper
• Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study.

  2006cited by this paper
• Improving caregiver well-being delays nursing home placement of patients with Alzheimer disease

  2006cited by this paper
• Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.

  2006cited by this paper
• Donepezil for mild cognitive impairment.

  2006cited by this paper
• Enhanced brain activity may precede the diagnosis of Alzheimer's disease by 30 years.

  2006cited by this paper
• Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment

  2006cited by this paper
• Lifestyle Risk and Delaying Factors

  2006cited by this paper
• In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses

  2006cited by this paper
• Cognitive training in Alzheimer's disease: a meta‐analysis of the literature

  2006cited by this paper
• Resveratrol--a boon for treating Alzheimer's disease?

  2006cited by this paper
• Comparison of the Saint Louis University mental status examination and the mini-mental state examination for detecting dementia and mild neurocognitive disorder--a pilot study.

  2006cited by this paper
• Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.

  2006cited by this paper
• Adding memantine to rivastigmine therapy in patients with mild-to-moderate alzheimer's disease: results of a 12-week, open-label pilot study.

  2006cited by this paper
• A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease.

  2006cited by this paper
• Inflammation, anti-inflammatory agents and Alzheimer disease: The last 12 years

  2006cited by this paper
• Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology

  2006cited by this paper
• Pharmacokinetic study of memantine in healthy and renally impaired subjects

  2006cited by this paper
• Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment.

  2006influential reference
• Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.

  2006cited by this paper
• Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo‐controlled double‐blind study

  2006cited by this paper
• Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production.

  2006cited by this paper
• Fruit and vegetable juices and Alzheimer's disease: the Kame Project.

  2006cited by this paper
• Exercise Is Associated with Reduced Risk for Incident Dementia among Persons 65 Years of Age and Older

  2006cited by this paper
• Dementia care: mental health effects, intervention strategies, and clinical implications.

  2006cited by this paper
• Mild cognitive impairment

  2006cited by this paper
• The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.

  2006cited by this paper
• A systematic review of assessment and treatment of moderate to severe Alzheimer's disease.

  2006cited by this paper
• Enhancing the Quality of Life of Dementia Caregivers from Different Ethnic or Racial Groups

  2006cited by this paper
• Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond

  2006cited by this paper
• Fish consumption and cognitive decline with age in a large community study.

  2005cited by this paper
• Measuring depression in nursing home residents with the MDS and GDS: an observational psychometric study

  2005cited by this paper
• Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.

  2005cited by this paper
• Reality orientation therapy combined with cholinesterase inhibitors in Alzheimer's disease: randomised controlled trial

  2005cited by this paper
• Memantine for dementia.

  2005cited by this paper
• The influence of psychotropic drugs on cerebral cell death: female neurovulnerability to antipsychotics

  2005cited by this paper
• Clinical trials in mild cognitive impairment: lessons for the future

  2005cited by this paper
• A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment

  2005cited by this paper
• Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study

  2005cited by this paper
• Vitamin E and donepezil for the treatment of mild cognitive impairment.

  2005cited by this paper
• Green Tea Epigallocatechin-3-Gallate (EGCG) Modulates Amyloid Precursor Protein Cleavage and Reduces Cerebral Amyloidosis in Alzheimer Transgenic Mice

  2005cited by this paper
• Atypical Antipsychotic Medications and Risk of Falls in Residents of Aged Care Facilities

  2005cited by this paper
• Caregiving burden and psychiatric morbidity in spouses of persons with mild cognitive impairment

  2005cited by this paper
• A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type.

  2005cited by this paper
• Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease

  2005cited by this paper
• Increased risk of cerebrovascular adverse events and death in elderly demented patients treated with atypical antipsychotics: what's a clinician to do?

  2005cited by this paper
• Donepezil: a review

  2005cited by this paper
• Changes in social support as mediators of the impact of a psychosocial intervention for spouse caregivers of persons with Alzheimer's disease.

  2005cited by this paper
• Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality

  2005cited by this paper
• Increasing trends in elderly persons' use of nonvitamin, nonmineral dietary supplements and concurrent use of medications.

  2005cited by this paper
• Can statin therapy really reduce the risk of Alzheimer's disease and slow its progression?

  2005cited by this paper
• Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies

  2005cited by this paper
• Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo*

  2005cited by this paper
• Reality orientation for dementia (Withdrawn Paper. 2000, art no. CD001119)

  2005cited by this paper
• Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years

  2005cited by this paper
• An active and socially integrated lifestyle in late life might protect against dementia.

  2004cited by this paper
• Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease

  2004cited by this paper
• Utilizing combination therapy in the treatment of Alzheimer’s disease

  2004cited by this paper
• Validity of Informant Reports About AD and MCI Patients’ Memory

  2004cited by this paper
• Sustained benefit of supportive intervention for depressive symptoms in caregivers of patients with Alzheimer's disease.

  2004cited by this paper
• Patient versus informant perspectives of Quality of Life in Mild Cognitive Impairment and Alzheimer's disease

  2004cited by this paper
• Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain

  2004cited by this paper
• Risk of Antipsychotic Drug Use in Patients with Alzheimer’s Disease Treated with Rivastigmine

  2004cited by this paper
• Physical activity, including walking, and cognitive function in older women.

  2004cited by this paper
• Walking and dementia in physically capable elderly men.

  2004cited by this paper
• P1-377 Safety, tolerability, and caregiver's impressions of combination therapy with rivastigmine and memantine for the treatment of Alzheimer's disease

  2004cited by this paper
• Patients with Alzheimer’s Disease May Be Particularly Susceptible to Adverse Effects of Statins

  2004cited by this paper
• Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia.

  2004cited by this paper
• Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.

  2004cited by this paper
• Neuroticism and longitudinal change in caregiver depression: impact of a spouse-caregiver intervention program.

  2004cited by this paper
• The effects of exercise training on elderly persons with cognitive impairment and dementia: a meta-analysis.

  2004cited by this paper
• Mild cognitive impairment as a diagnostic entity

  2004cited by this paper
• Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions

  2004cited by this paper
• Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment

  2004cited by this paper

• Elecsys CSF AD immunoassays: Sample stability for a new pre‐analytical protocol for fresh CSF

  2025cites this paper
• Dual Inhibitors of Acetylcholinesterase and Monoamine Oxidase-B for the Treatment of Alzheimer’s Disease

  2025cites this paper
• A Multi-Label Deep Learning Model for Detailed Classification of Alzheimer's Disease

  2025cites this paper
• Knowledge and Beliefs About Medical and Non‐Medical Interventions to Control Alzheimer’s Disease Among Latinos in New York City

  2025cites this paper
• Synthesis and evaluation of lipoic acid - donepezil hybrids for Alzheimer's disease using a straightforward strategy.

  2024cites this paper
• Impact of Nutritional Interventions on Alzheimer's Disease Progression: A Comprehensive Review of Dietary Patterns, Mechanisms, and Clinical Outcomes

  2024cites this paper
• A narrative review of phase III and IV clinical trials for the pharmacological treatment of Huntington’s disease in adults

  2024cites this paper
• Kaempferol: Paving the path for advanced treatments in aging-related diseases.

  2024cites this paper
• Unveiling the Complex Role of Exosomes in Alzheimer’s Disease

  2024cites this paper
• Ginkgo biloba: A Leaf of Hope in the Fight against Alzheimer’s Dementia: Clinical Trial Systematic Review

  2024cites this paper
• Investigation of Potential Drug Targets for Cholesterol Regulation to Treat Alzheimer’s Disease

  2023cites this paper
• Analyzing global features of magnetic resonance images in widespread neurodegenerative diseases: new hope to understand brain mechanism and robust neurodegenerative disease diagnosis

  2023cites this paper
• Polyherbal and Multimodal Treatments: Kaempferol- and Quercetin-Rich Herbs Alleviate Symptoms of Alzheimer’s Disease

  2023cites this paper
• Multifunctional Nanocarriers for Alzheimer’s Disease: Befriending the Barriers

  2023influential citation
• RAGE: a potential target for Epimedium’s anti-neuroinflammation role in vascular dementia—insights from network pharmacology and molecular simulation

  2023cites this paper
• Exploring the role of COX-2 in Alzheimer's disease: Potential therapeutic implications of COX-2 inhibitors

  2023cites this paper
• Effects of GV1001 on Language Dysfunction in Patients With Moderate-to-Severe Alzheimer’s Disease: Post Hoc Analysis of Severe Impairment Battery Subscales

  2023cites this paper
• Drug Discovery and Development Targeting Dementia

  2023cites this paper
• ADCB: An Alzheimer's disease simulator for benchmarking observational estimators of causal effects

  2022cites this paper
• Reducing PDK1/Akt Activity: An Effective Therapeutic Target in the Treatment of Alzheimer’s Disease

  2022cites this paper
• Pyrazoline Containing Compounds as Therapeutic Targets for Neurodegenerative Disorders

  2022cites this paper
• Rivastigmine

  2021cites this paper
• The Pharmacological Action of Kaempferol in Central Nervous System Diseases: A Review

  2021cites this paper
• Exosomes in Alzheimer’s Disease: From Being Pathological Players to Potential Diagnostics and Therapeutics

  2021cites this paper
• The Role of Medical Acupuncture Therapy in Alzheimer's Disease

  2021cites this paper
• ADCB: An Alzheimer's disease benchmark for evaluating observational estimators of causal effects

  2021cites this paper
• Transferrin-Pep63-liposomes accelerate the clearance of Aβ and rescue impaired synaptic plasticity in early Alzheimer’s disease models

  2021cites this paper
• Structure, synthesis, biosynthesis, and activity of the characteristic compounds from Ginkgo biloba L.

  2021cites this paper
• Role of Propolis as a pharmaceutical candidate on interleukin-1β proinflammatory cytokine expression in Alzheimer's rat

  2021cites this paper
• Melissa officinalis (lemon balm)

  2021cites this paper
• A multi-parameter evaluation of the neuroprotective and cognitive-enhancing effects of Origanum onites L. (Turkish Oregano) essential oil on scopolamine-induced amnestic rats

  2021cites this paper
• STRATEGIES FOR MANAGEMENT OF ALZHEIMER’S DISEASE: A REVIEW

  2020cites this paper
• Interrelation of thermodynamic sublimation characteristics with crystal structure: adamantane and memantine derivatives of sulfonamide molecular crystals

  2020cites this paper
• The Impact of Natural Compounds on S-Shaped Aβ42 Fibril: From Molecular Docking to Biophysical Characterization

  2020cites this paper
• Combination Drug Therapy for the Management of Alzheimer’s Disease

  2020cites this paper
• Preparation and in vitro activity of single chain antibodies against Alzheimer's disease.

  2020cites this paper
• Therapeutic potentials of neural stem cells in Alzheimer's disease.

  2020cites this paper
• Molecular simulations of amyloid beta assemblies

  2020cites this paper
• Cognitive Improvements After Intermittent Deep Brain Stimulation of the Nucleus Basalis of Meynert in a Transgenic Rat Model for Alzheimer’s Disease: A Preliminary Approach

  2019cites this paper
• A review on complementary and alternative treatments for dementia

  2019cites this paper
• Mitochondrial dysfunction and Alzheimer’s disease: prospects for therapeutic intervention

  2019cites this paper
• New APOE-related therapeutic options for Alzheimer’s disease

  2019cites this paper
• Discovering Biomarkers of Alzheimer's Disease by Statistical Learning Approaches

  2019cites this paper
• Repurposing of Nitroxoline Drug for the Prevention of Neurodegeneration.

  2019cites this paper
• Dementia treatment versus prevention

  2019cites this paper
• Novel AChE and BChE inhibitors using combined virtual screening, text mining and in vitro binding assays

  2019cites this paper
• Intestinal mucosal metabolites-guided detection of trace-level ginkgo biloba extract metabolome.

  2019cites this paper
• Therapeutic implications of anti-inflammatory natural products in Alzheimer’s disease

  2019cites this paper
• Synthesis, characterization, crystal structure of schiff base compound as potent acetylcholinesterase inhibitors and their molecular modeling study

  2019cites this paper
• ONO-8590580, a Novel GABAA α5 Negative Allosteric Modulator Enhances Long-Term Potentiation and Improves Cognitive Deficits in Preclinical Models

  2018cites this paper
• Neurologie, Neurochirurgie Für Sie gelesen: Randomized Double-Blind, Parallel-Group 48-Week Study for Efficacy and Safety of a Higher-Dose Rivastigmine Patch (15 vs. 10 cm2) in

  2018cites this paper
• Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer’s disease

  2018influential citation
• Anti-neuroinflammatory Potential of Natural Products in Attenuation of Alzheimer's Disease

  2018cites this paper
• Identification of crizotinib derivatives as potent SHIP2 inhibitors for the treatment of Alzheimer's disease.

  2018cites this paper
• Kaempferol attenuates cognitive deficit via regulating oxidative stress and neuroinflammation in an ovariectomized rat model of sporadic dementia

  2018cites this paper
• Hypoxia and alzheimer's disease: the processing of amyloid precursor protein and the role of prolyl-hydroxylase 3 in microglia.

  2018cites this paper
• Biophenols: Impacts and Prospects in Anti-Alzheimer Drug Discovery

  2018cites this paper
• Characterization of epigenetic and transcriptional changes in aging and Alzheimer’s disease

  2017cites this paper
• Discovery of thienopyrrolotriazine derivatives to protect mitochondrial function against Aβ-induced neurotoxicity.

  2017cites this paper
• Therapeutic potentials of herbal drugs for Alzheimer’s disease—An overview.

  2017cites this paper
• Rôle du jeûne et de la perturbation de la cascade de signalisation de l'insuline sur le clivage du précurseur de la protéine amyloïde (APP)

  2017influential citation
• Depression and PTSD as Predictors of Dementia and Other Cognitive Disorders among Veterans based on Race and Sex

  2017cites this paper
• Evaluation of selected dye compounds as inhibitors of monoamine oxidase

  2017cites this paper
• Acupuncture for patients with mild to moderate Alzheimer’s disease: a randomized controlled trial

  2017cites this paper
• Alzheimer,s Disease Risk and Progression: The Role of Nutritional Supplements and their Effect on Drug Therapy Outcome

  2016cites this paper
• miRNAs as therapeutic agents in neurodegeneration : a pilot study

  2016cites this paper
• Efficient Synthesis and Discovery of Schiff Bases as Potent Cholinesterase Inhibitors.

  2016cites this paper
• Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia

  2016cites this paper
• Herbal Medicine for the Treatment of Vascular Dementia: An Overview of Scientific Evidence

  2016cites this paper
• Ionic Liquid-Promoted Synthesis and Cholinesterase Inhibitory Activity of Highly Functionalized Spiropyrrolidines

  2015cites this paper
• Nuevos abordajes terapéuticos basados en la melatonina y sus derivados para el tratamiento de la enfermedad de Alzheimer y el ictus

  2015cites this paper
• The Molecular Basis of Autism

  2015cites this paper
• Inhibition of Alzheimer’s type toxic aggregates of tau with fungal secondary metabolites

  2015cites this paper
• Attitude Towards Alzheimer's Disease Among Undergraduate Students of University of the West Indies, Trinidad and Tobago.

  2015cites this paper
• Longitudinal Associations between Survival in Alzheimer's Disease and Cholinesterase Inhibitor Use, Progression, and Community-Based Services

  2015cites this paper
• Molecular Basis of Cholinergic Changes in Autism Spectrum Disorders and Relevance for Treatment Interventions

  2015cites this paper
• Potential neuroprotective effects of cinnamon

  2015cites this paper
• Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease

  2015cites this paper
• The pharmacological management of Alzheimer's disease

  2015cites this paper
• Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?

  2015cites this paper
• Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease.

  2015cites this paper
• Annual Cognitive Assessment for Older Adults: Update for Nurses

  2015cites this paper
• In Vivo Neuroprotective Effects of Cinnamon Bioactive Compounds in C. elegans and D. melanogaster

  2015cites this paper
• Syntheses, Cholinesterases Inhibition, and Molecular Docking Studies of Pyrido[2,3‐b]pyrazine Derivatives

  2015cites this paper
• A review on Alzheimer’s disease pathophysiology and its management: an update

  2015cites this paper
• Cholinesterase inhibitory activity versus aromatic core multiplicity: a facile green synthesis and molecular docking study of novel piperidone embedded thiazolopyrimidines.

  2014cites this paper
• Role of nanomedicines in delivery of anti-acetylcholinesterase compounds to the brain in Alzheimer's disease.

  2014cites this paper
• Ionic liquid mediated synthesis and molecular docking study of novel aromatic embedded Schiff bases as potent cholinesterase inhibitors.

  2014cites this paper
• Farmakoterapia choroby Alzheimera i innych otępień w praktyce: który lek, kiedy i dla kogo?

  2014cites this paper
• Pathways to dementia: genetic predictors of cognitive and brain imaging endophenotypes in Alzheimer's disease

  2014cites this paper
• APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study

  2013cites this paper
• Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders.

  2013cites this paper
• Transdermal Is Better than Oral: Observational Research of the Satisfaction of Caregivers of Patients with Alzheimer’s Disease Treated with Rivastigmine

  2013cites this paper
• Physician-assisted suicide of patients with dementia. A medical ethical analysis with a special focus on patient autonomy.

  2013cites this paper
• Efficacy of Memantine, Donepezil, or Their Association in Moderate-Severe Alzheimer's Disease: A Review of Clinical Trials

  2013cites this paper
• Adherence to Cholinesterase Inhibitors in Alzheimer's Disease: A Review

  2013cites this paper
• Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer's disease

  2013cites this paper
• As time goes by.

  2013cites this paper
• Preserving independence: treatment decisions over 4 years in an elderly woman with cognitive decline.

  2013cites this paper
• An expedient, ionic liquid mediated multi-component synthesis of novel piperidone grafted cholinesterase enzymes inhibitors and their molecular modeling study.

  2013cites this paper